Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Current Deferred Revenue: 2012-2025

Historic Current Deferred Revenue for Ptc Therapeutics (PTCT) over the last 9 years, with Sep 2025 value amounting to $1.7 million.

  • Ptc Therapeutics' Current Deferred Revenue was N/A to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $5.5 million for FY2024, which is 587.27% up from last year.
  • Per Ptc Therapeutics' latest filing, its Current Deferred Revenue stood at $1.7 million for Q3 2025, which was down 82.67% from $9.8 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Current Deferred Revenue ranged from a high of $12.8 million in Q1 2025 and a low of $214,000 during Q1 2023.
  • Moreover, its 3-year median value for Current Deferred Revenue was $1.7 million (2025), whereas its average is $4.6 million.
  • Per our database at Business Quant, Ptc Therapeutics' Current Deferred Revenue plummeted by 81.73% in 2021 and then skyrocketed by 587.27% in 2024.
  • Ptc Therapeutics' Current Deferred Revenue (Quarterly) stood at $1.9 million in 2021, then reached $1.4 million in 2022, then crashed by 40.71% to $801,000 in 2023, then soared by 587.27% to $5.5 million in 2024, then reached $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $9.8 million for Q2 2025, and $12.8 million during Q1 2025.